Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ENLIGHTEN 2: A Phase III, Randomized, Blinded, Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults

NCT05295459 is registered in ClinicalTrials.gov with Lyra Therapeutics as lead sponsor.

NCT NCT05295459
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05295459 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ENLIGHTEN 2: A Phase III, Randomized, Blinded, Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults
Lead sponsor
Lyra Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
May 13, 2022
Completion date
April 2, 2025
Enrollment
182 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

chronic rhinosinusitis (diagnosis), chronic sinusitis